Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Perspectives from ASCO 2018: Highlights in drugging PIK3CA-mutated tumours: The SANDPIPER and MATCH trials

Dejan Juric reports on the results presented at ASCO 2018 from studies that tested addition of selective PIK3CA inhibitor in selected populations of patients, but the treatment caused considerable side effects.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.